These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38062121)

  • 1. Advances in incretin-based therapeutics for obesity.
    Rosenkilde MM
    Nat Rev Endocrinol; 2024 Feb; 20(2):67-68. PubMed ID: 38062121
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy for obesity based on gastrointestinal hormones.
    Bagger JI; Christensen M; Knop FK; Vilsbøll T
    Rev Diabet Stud; 2011; 8(3):339-47. PubMed ID: 22262071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
    Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity.
    Karras S; Goulis DG; Mintziori G; Katsiki N; Tzotzas T
    Curr Vasc Pharmacol; 2012 Nov; 10(6):781-91. PubMed ID: 22272906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus.
    Nisal K; Kela R; Khunti K; Davies MJ
    BMC Med; 2012 Nov; 10():152. PubMed ID: 23198896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials.
    Kyriakos G; Quiles-Sanchez LV; Garmpi A; Farmaki P; Kyre K; Gkogkos S; Savvanis S; Memi E
    Curr Cardiol Rev; 2020; 16(4):253-257. PubMed ID: 31161994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expanding role of incretin-based therapies: how much should we expect?
    Haluzik M
    J Endocrinol; 2014 Apr; 221(1):E1-2. PubMed ID: 24623799
    [No Abstract]   [Full Text] [Related]  

  • 10. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease.
    Andreasen CR; Andersen A; Vilsbøll T
    Diabetologia; 2023 Oct; 66(10):1846-1858. PubMed ID: 37498367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tapping incretin-based therapy for type 2 diabetes.
    Appel SJ
    Nursing; 2011 Mar; 41(3):49-51. PubMed ID: 21326056
    [No Abstract]   [Full Text] [Related]  

  • 14. [Incretin-based co- and tri-agonists : Innovative polypharmacology for the treatment of obesity and diabetes].
    Harger A; Stemmer K; Tschöp MH; Müller TD
    Internist (Berl); 2019 Sep; 60(9):895-902. PubMed ID: 31346639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted intestinal delivery of incretin secretagogues-towards new diabetes and obesity therapies.
    Gribble FM; Meek CL; Reimann F
    Peptides; 2018 Feb; 100():68-74. PubMed ID: 29412834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity pharmacotherapy: incretin action in the central nervous system.
    Boer GA; Hay DL; Tups A
    Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin based therapies: do they hold their promise?
    Holst JJ
    J Diabetes; 2012 Mar; 4(1):4-7. PubMed ID: 22248344
    [No Abstract]   [Full Text] [Related]  

  • 18. Problem or solution: The strange story of glucagon.
    Scott RV; Bloom SR
    Peptides; 2018 Feb; 100():36-41. PubMed ID: 29412829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapies for type 2 diabetes mellitus: New therapeutic mechanisms.
    Kennedy L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S2-3. PubMed ID: 19952299
    [No Abstract]   [Full Text] [Related]  

  • 20. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S; Collier A; Elhadd T; Malik I
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.